Drug Approval | November 19, 2022
Strides receives USFDA approval for Potassium Chloride Oral Solution
The approval further strengthens the Potassium Chloride franchise for the company.
The approval further strengthens the Potassium Chloride franchise for the company.
The product is expected to be launched by Q4 FY23.
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Subscribe To Our Newsletter & Stay Updated
